Healthtech startup MrMed, a specialty pharmacy platform focused on critical and complex therapies, recorded 123 percent year-on-year revenue growth in FY26, taking revenue to INR 74.3 crore, and closed the year EBITDA positive.

The company has served over 1 lakh patients during the year, and its reach widened too. Patients ordered from 4,000 plus towns, nearly 66percent of revenue came from outside metro cities, and MrMed now serves 19,000 plus pincodes. During FY26, patients saved INR 44.3 crore on their medicines, an average saving of 41.6 percent.

MrMed currently covers 100 plus rare diseases across 35 plus specialty therapy areas. It operates five cold-chain fulfilment hubs, built to serve patients who need temperature-sensitive and complex therapies across regions.

Devashish Singh, Co-founder and CEO, MrMed, said, “A patient on a specialty therapy needs the same medicine, reliably and affordably, month after month. Outside the metros, that is where the system usually breaks, and it is where two-thirds of our revenue now comes from. Doubling the business while staying EBITDA positive tells us this model can grow sustainably. Our focus now is to take it deeper into Tier II and Tier III towns, and to use technology and AI to make every refill simpler for patients and caregivers.”

MrMed expanded its infrastructure through FY26 and into FY27. It opened its Bengaluru corporate office in June 2025, followed by a Bengaluru fulfillment hub in September 2025. In FY27, it added fulfillment hubs in Guwahati in April 2026 and Mumbai in September 2026. The company has also moved to larger, more central premises in Bengaluru and Delhi, and its Chennai head office moves to larger premises in October 2026.

Saurab Jain, Co-founder and CBO, MrMed, said, “Every new hub starts with one question: can a patient in a smaller town get a specialty medicine as reliably as someone in a metro? Guwahati and Mumbai bring that within reach for the Northeast and western India. Our sourcing relationships and cold chain are what let us add reach without adding risk for the patient.”

Over the next 12 to 18 months, MrMed plans to deepen its presence across Tier 2 and Tier 3 towns through its expanded hub network, including stronger coverage of the Northeast through Guwahati and western markets through Mumbai. It also plans to add more patient-focused verticals around medicine access, with the aim of becoming a single destination for super-specialty patients and their caregivers across India.